UTMB Tests Tirzepatide to Cut Biologic Aging 10%-15%
Updated
Updated · abcnews.com · Aug 19
UTMB Tests Tirzepatide to Cut Biologic Aging 10%-15%
3 articles · Updated · abcnews.com · Aug 19
Summary
University of Texas Medical Branch researchers are launching one of the first clinical trials to test whether tirzepatide can slow human aging, targeting a 10% to 15% reduction in biologic aging.
The study will track adults aged 55 to 70 who qualify for weight-loss treatment, measuring biological age markers alongside inflammation, cognitive function, strength and mobility.
Interest in the idea has grown after a separate UC San Diego and Case Western study of 84 adults with HIV found 32 weeks of semaglutide produced DNA-based changes consistent with slower aging.
Researchers say those signals are preliminary, and there is still no evidence that healthy people should take GLP-1 drugs for longevity.